Ignite Creation Date:
2024-05-06 @ 4:06 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04872790
Status:
RECRUITING
Last Update Posted:
2023-12-20
First Post:
2021-03-19
Brief Title:
Venetoclax Dasatinib Prednisone Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Sponsor:
OHSU Knight Cancer Institute
Organization:
OHSU Knight Cancer Institute
Conditions & Keywords Data
Conditions:
| Name |
|---|
| B Acute Lymphoblastic Leukemia |
| B Acute Lymphoblastic Leukemia With t922q341q112 BCR-ABL1 |
| Mixed Phenotype Acute Leukemia |
| Recurrent B Acute Lymphoblastic Leukemia |
| Recurrent Mixed Phenotype Acute Leukemia |
Keywords: